Toripalimab Combined With Chemoradiotherapy Followed by Toripalimab Maintenance Therapy for High-risk Locally Advanced Cervical Cancer: the Phase II Single-arm TorCH -CC Study.

This document provides information about a clinical trial in China for the drug Toripalimab, which is being tested as a treatment for high-risk locally advanced cervical cancer (HR-LACC). The trial aims to assess the effectiveness and safety of Toripalimab combined with chemoradiotherapy (CRT) followed by Toripalimab maintenance therapy. The primary goal of the study is to improve the 2-year progression-free survival rate for HR-LACC patients. The trial is currently recruiting participants and is expected to be completed by December 2026. The eligibility criteria include having confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. The study is being conducted by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. [Extracted from the article]